TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Summary

To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy. ctDNA is genetic material from tumor cells that can be found and measured in the blood.

Timeline

Start

2022-06-06

Primary completion

2027-05-15

Completion

2027-05-15

Outcome

Met primary endpoint

paper In the SC, two patients (6.7%) had spontaneous ctDNA clearance at 3 months (P = .0034) sustained at 6 months (P = .025). PMID 40669021 ↗

Publications

• Pellatt AJ, Bent A, Hornstein N, Parseghian C, Huey R, Raghav K, Morris V, Overman M, Morelli P, Willis J, Le P, Shen JP, Kee B, Eluri M, Higbie V, Alfaro-Munoz K, Aziz K, Kell R, Sun R, Kopetz S, Dasari A. Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT. JCO Precis Oncol. 2025 Jul;9:e2500142. doi: 10.1200/PO-25-00142. Epub 2025 Jul 16.

Drugs

Indications